PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.\', \'School of Medicine, Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany.\', \'Department of Traumatology, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.\', \'Department of Neurosurgery, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.\', \'School of Medicine, Hospital Pharmacy, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany.\', \'School of Medicine, Institute of Virology, Technical University of Munich, Munich, Germany.\', \'Institute of Medical Statistics and Epidemiology, Technical University of Munich, Munich, Germany.\', \'Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Munich, Germany. roman.iakoubov@mri.tum.de.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s15010-021-01657-y
?:hasPublicationType
?:journal
  • Infection
is ?:pmid of
?:pmid
?:pmid
  • 34244967
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.171
?:rankingScore_hIndex
  • 64
is ?:relation_isRelatedTo_publication of
?:title
  • Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all